Quality of life assessment in clinical trials - guidelines and a checklist for protocol writers: The U.K. Medical Research Council experience

European Journal of Cancer Part A

Volumn 33, Issue 1, 1997, Pages 20-28

  Fayers, P M ^a   Hopwood, P ^b   Harvey, A ^a   Girling, D J ^a   Machin, D ^a   Stephens, R ^a  

^a MEDICAL RESEARCH COUNCIL   (United Kingdom)

^b CHRISTIE HOSPITAL   (United Kingdom)

Author keywords

cancer clinical trials; patient compliance; protocol design; quality of life; randomised controlled trials

Indexed keywords

CANCER; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; HUMAN; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; REVIEW;

EID: 0031020394     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(96)00412-1     Document Type: Article

References (44)

1. 1. Fayers PM, de Haes JCJM. Editorial (unsigned): Quality of life and clinical trials. Lancet 1995, 346, 1-2.
2. 2. Fayers PM, Jones DR. Measuring and analysing quality of life in cancer clinical trials: a review. Stat Med 1983, 2, 429-446.
3. 3. Medical Research Council Lung Cancer Working Party. Survival, adverse reactions and quality of life during combination chemotherapy compared with selective palliative treatment for small-cell lung cancer. Report to the Medical Research Council by its Lung Cancer Working Party. Respir Med 1989, 83, 51-58.
4. 4. Medical Research Council Lung Cancer Working Party. Controlled trial of twelve versus six courses of chemotherapy in the treatment of small-cell lung cancer. Report to the Medical Research Council by its Lung Cancer Working Party. Br J Cancer 1989, 59, 584-590.
5. 5. Fayers PM, Bleehen NM, Girling DJ, Stephens RJ. Assessment of quality of life in small-cell lung cancer using a Daily Diary Card developed by the Medical Research Council Lung Cancer Working Party. Br J Cancer 1991, 64, 299-306.
6. 6. Medical Research Council Lung Cancer Working Party. Inoperable non-small-cell lung cancer (NSCLC): a Medical Research Council randomised trial of palliative radiotherapy with two fractions or ten fractions. Report to the Medical Research Council by its Lung Cancer Working Party. Br J Cancer 1991, 63, 265-270.
7. 7. Medical Research Council Lung Cancer Working Party. A Medical Research Council (MRC) randomized trial of palliative radiotherapy with 2 fractions or a single fraction in patients with inoperable non-small-cell lung-cancer (NSCLC) and poor performance status. Br J Cancer 1992, 65, 934-941.
8. 8. Medical Research Council Lung Cancer Working Party. A randomised trial of three or six courses of etoposide, cyclophosphamide, methotrexate and vincristine or six courses of etoposide and ifosfamide in small cell lung cancer (SCLC). II: Quality of life. Br J Cancer 1993, 68, 1157-1166.
9. 9. Medical Research Council Lung Cancer Working Party. Randomised trial of four-drug vs less intensive two-drug chemotherapy in the palliative treatment of patients with small-cell lung cancer (SCLC) and poor prognosis. Br J Cancer 1996, 76, 406-413.
10. 10. Medical Research Council Lung Cancer Working Party. Randomized trial of palliative two-fraction versus more intensive 13-fraction radiotherapy for patients with inoperable non-small cell lung cancer and good performance status. Clin Oncol 1966, 8, 167-175.
11. 11. Fayers PM. MRC Quality of life studies using a Daily Diary Card - practical lessons learned from cancer trials. Qual Life Res 1995, 4, 343-352.
12. 12. de Haes JCJM, van Knippenberg FCE, Neijt JP. Measuring psychological and physical distress in cancer patients: structure and application of the Rotterdam Symptom Checklist. Br J Cancer 1990, 62, 1034-1038.
13. 13. Zigmond AS, Snaith RP. The Hospital Anxiety and Depression Scale. Acta Psychiatr Scand 1983, 67, 361-370.
14. 14. Aaronson NK, Ahmedzai S, Bergman B, et al. The Puropean Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 1993, 85, 365-376.
15. 15. Hopwood P, Harvey A, Gibson D, Stephens RJ, Girling DJ, Parmar MKB. Survey of the administration of quality of life (QL) questionnaires in three multicentre randomised trials in cancer. In preparation 1997.
16. 16. Osoba D. The Quality of Life Committee of the Clinical Trials Group of the National Cancer Institute of Canada: organization and functions. Qual Life Res 1992, 1, 211-218.
17. 17. Sadura A, Pater J, Osoba D, Levine M, Palmer M, Bennett K. Quality-of-life assessment: patient compliance with questionnaire completion. J Natl Cancer Inst 1992, 84, 1023-1026.
18. 18. Hurny C, Bernard J, Joss R, et al. Feasibility of quality of life assessment in a randomized phase III trial of small cell lung cancer - a lesson from the real world - the Swiss Group for Clinical Cancer Research SAKK. Ann Oncol 1992, 3, 825-831.
19. 19. de Haes JCJM - chairperson, Liaison Subgroup. Guidelines for Inclusion of Quality of Life Measures in Clinical Oncology Trials. Brussels, European Organization for Research and Treatment of Cancer.
20. 20. Gotay CC, Korn EL, McCabe MS, Moore TD, Cheson BD. Quality-of-life assessment in cancer treatment protocols: research issues in protocol development. J Natl Cancer Inst 1992, 84, 575-579.
21. 21. Bowling A. Measuring Health: A Review of Quality of Life Measurement Scales. Philadelphia, Open University Press, 1991.
22. 22. Bowling A. Measuring Disease: A Review of Disease-Specific Quality of Life Measurement Scales. Philadelphia, Open University Press, 1995.
23. 23. Anderson RT, Aaronson NK, Wilkin D. Critical review of the international assessments of health-related quality of life. Qual Life Res 1993, 2, 369-395.
24. 24. Hopwood P, Stephens RJ, Machin D, for the Medical Research Council Lung Cancer Working Party. Approaches to the analysis of quality of life data: experiences gained from a Medical Research Council Lung Cancer Working Party palliative chemotherapy trial. Qual Life Res 1994, 3, 339-352.
25. 25. Finkelstein DM, Cassileth BR, Bonomi PD, Ruckdeschel JC, Ezdinli EZ, Wolter JM. A pilot study of the Functional Living Index-Cancer (FLIC) scale for the assessment of quality of life for metastatic lung cancer patients. An Eastern Cooperative Oncology Group study. Am J Clin Oncol (CCT) 1988, 11, 630-633.
26. 26. Ganz PA, Haskell CM, Figlin RA, La SN, Siau J. Estimating the quality of life in a clinical trial of patients with metastatic lung cancer using the Karnofsky performance status and the Functional Living Index-Cancer. Cancer 1988, 61, 849-856.
27. 27. Fossa SD, Aaronson NK, Newling D, et al. Quality of life and treatment of hormone resistant metastatic prostatic cancer. Eur J Cancer 1990, 26, 1133-1136.
28. 28. Geddes DM, Dones L, Hill E, et al. Quality of life during chemotherapy for small cell lung cancer: assessment and use of a daily diary card in a randomized trial. Eur J Cancer 1990, 26, 484-492.
29. 29. Earl HM, Rudd RM, Spiro SG, et al. A randomised trial of planned versus as required chemotherapy in small cell lung cancer: a Cancer Research Campaign trial. Br J Cancer 1991, 64, 566-572.
30. 30. Cox DR, Fitzpatrick R, Fletcher AE, et al. Quality-of-life assessment: can we keep it simple? J R Stat Soc 1992, 155, 353-393.
31. 31. Hunt SM, McEwen J, McKenna SP. Measuring Health Status. London, Croom Helm, 1986.
32. 32. Slevin ML, Stubbs L, Plant HJ, et al. Attitudes to chemotherapy: comparing views of patients with cancer with those of doctors, nurses, and general public. Br Med J 1990, 300, 1458-1460.
33. 33. Olver IN, Matthews JP, Bishop JF, Smith RA. The roles of patient and observer assessments in anti-emetic trials. Eur J Cancer 1994, 30A, 1223-1227.
34. 34. Bjordal K, Freng A, Thorvik J, Kaasa S. Patient self-reported and clinician rated quality of life in head and neck cancer patients; a cross sectional study. Eur J Cancer 1995, 31B, 340-345.
35. 35. Faller H, Lang H, Schilling S. Emotional distress and hope in lung cancer patients, as perceived by patients, relatives, physicians, nurses and interviewers. Psych Oncol 1995, 4, 21-31.
36. 36. Larue F, Colleau SM, Brasseur L, Cleeland CS. Multicentre study of cancer pain and is treatment in France. Br Med J 1995, 310, 1034-1037.
37. 37. Sprangers MAG, Aaronson NK. The role of health care providers and significant others in evaluating the quality of life of patients with chronic disease: a review. J Clin Epidemiol 1992, 45, 743-760.
38. 38. Lampic C, Nordin K, Sjödén P-O. Agreement between cancer patients and their physicians in the assessment of patient anxiety at follow-up visits. Psych Oncol 1995, 4, 301-310.
39. 39. Lomas J, Pickard L, Mohide A. Patient versus clinician item generation for quality of life measures. Med Care 1987, 25, 764-769.
40. 40. Stephens RJ, for the British Medical Research Council Lung Cancer Working Party. Quality of life (QL) in randomised clinical trials: are the doctors' assessments as valid as the patients? Lung Cancer 1994, 11 (Suppl. 1), 81.
41. 41. Glimelius B, Hoffman K, Graf W, Pahlman L, Sjoden PO. Quality of life during chemotherapy in patients with symptomatic advanced colorectal cancer. The Nordic Gastrointestinal Tumor Adjuant Therapy Group. Cancer 1994, 73, 556-562.
42. 42. Cook DJ, Guyatt GH, Juniper EF, et al. Interviewer versus self-administered questionnaires in developing a disease-specific, health-related quality of life instrument for asthma. J Clin Epidemiol 1993, 46, 529-534.
43. 43. Bremer BA, McCauley CR. Quality-of-life measures: hospital interview versus home questionnaire. Health Psychol 1986, 5, 171-177.
44. 44. Moum T. Yea-saying and mood-of-the-day effects in self-reported quality of life. Social Indicators Research 1988, 20, 117-139.